{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:00:59Z","timestamp":1792083659868,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Center for Advancing Translational Sciences of the National Institutes of Health","award":["KL2TR002241"],"award-info":[{"award-number":["KL2TR002241"]}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["U01CE002780"],"award-info":[{"award-number":["U01CE002780"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Michigan Behavioral Workforce Center","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Subst Abuse Treat Prev Policy"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Evidence demonstrates that medications for treating opioid use disorder (MOUD) \u2014namely buprenorphine, methadone, and extended-release naltrexone\u2014are effective at treating opioid use disorder (OUD) and reducing associated harms. However, MOUDs are heavily underutilized, largely due to the under-supply of providers trained and willing to prescribe the medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To understand comparative beliefs about MOUD and barriers to MOUD, we conducted a mixed-methods study that involved focus group interviews and an online survey disseminated to a random group of licensed U.S. physicians, which oversampled physicians with a preexisting waiver to prescribe buprenorphine. Focus group results were analyzed using thematic analysis. Survey results were analyzed using descriptive and inferential statistical methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Study findings suggest that physicians have higher perceptions of efficacy for methadone and buprenorphine than for extended-release naltrexone, including for patients with co-occurring mental health disorders. Insurance obstacles, such as prior authorization requirements, were the most commonly cited barrier to prescribing buprenorphine and extended-release naltrexone. Regulatory barriers, such as the training required to obtain a federal waiver to prescribe buprenorphine, were not considered significant barriers by many physicians to prescribing buprenorphine and naltrexone in office-based settings. Nor did physicians perceive diversion to be a prominent barrier to prescribing buprenorphine. In focus groups, physicians identified financial, logistical, and workforce barriers\u2014such as a lack of addiction treatment specialists\u2014as additional barriers to prescribing medications to treat OUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Additional education is needed for physicians regarding the comparative efficacy of different OUD medications. Governmental policies should mandate full insurance coverage of and prohibit prior authorization requirements for OUD medications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13011-020-00312-3","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T08:02:53Z","timestamp":1600070573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder"],"prefix":"10.1186","volume":"15","author":[{"given":"Rebecca L.","family":"Haffajee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6307-6369","authenticated-orcid":false,"given":"Barbara","family":"Andraka-Christou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Attermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cupito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Buche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela J.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,14]]},"reference":[{"key":"312_CR1","unstructured":"Hedegaard H, Mini\u00f1o AM, Warner M. Drug overdose deaths in the United States, 1999\u20132018. NCHS Data Brief, no 356. Hyattsville: National Center for Health Statistics; 2020."},{"key":"312_CR2","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/jama.2015.10345","volume":"314","author":"B Saloner","year":"2015","unstructured":"Saloner B, Karthikeyan S, et al. Changes in Substance Abuse Treatment Use Among Individuals With Opioid Use Disorders in the United States, 2004\u20132013. JAMA. 2015;314:1515.","journal-title":"JAMA"},{"key":"312_CR3","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1016\/j.amepre.2017.12.022","volume":"54","author":"RL Haffajee","year":"2018","unstructured":"Haffajee RL, Bohnert ASB, Lagisetty PA. Policy pathways to address provider workforce barriers to buprenorphine treatment. Am J Prev Med. 2018;54:S230\u2013S42.","journal-title":"Am J Prev Med"},{"key":"312_CR4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1056\/NEJMp1804059","volume":"379","author":"B Saloner","year":"2018","unstructured":"Saloner B, Stoller KB, Alexander GC. Moving addiction care to the mainstream \u2014 improving the quality of buprenorphine treatment. N Engl J Med. 2018;379:4\u20136.","journal-title":"N Engl J Med"},{"key":"312_CR5","volume-title":"Medications for Opioid Use Disorder Save Lives","author":"National Academies of Sciences E, and Medicine","year":"2019","unstructured":"National Academies of Sciences E, and Medicine. Medications for Opioid Use Disorder Save Lives. Washington D.C.: National Academies of Sciences, Engineering, and Medicine 2019; 2019. Report No: 9780309486484."},{"issue":"2","key":"312_CR6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622.","journal-title":"JAMA Netw Open"},{"key":"312_CR7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","volume":"169","author":"MR Larochelle","year":"2018","unstructured":"Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality. Ann Intern Med. 2018;169:137\u201345.","journal-title":"Ann Intern Med"},{"key":"312_CR8","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2105\/AJPH.2012.301049","volume":"103","author":"RP Schwartz","year":"2013","unstructured":"Schwartz RP, Gryczynski J, O'Grady KE, Sharfstein JM, Warren G, Olsen Y, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. Am J Public Health. 2013;103:917\u201322.","journal-title":"Am J Public Health"},{"key":"312_CR9","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","volume":"105","author":"CM Jones","year":"2015","unstructured":"Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105:e55\u201363.","journal-title":"Am J Public Health"},{"issue":"6","key":"312_CR10","doi-asserted-by":"crossref","first-page":"e196373","DOI":"10.1001\/jamanetworkopen.2019.6373","volume":"2","author":"R Haffajee","year":"2019","unstructured":"Haffajee R, Lin LA, Bohnert ASB, Goldstick JE. Characteristics of U.S. Counties with High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder. JAMA Netw Open. 2019;2(6):e196373.","journal-title":"JAMA Netw Open"},{"key":"312_CR11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11920-017-0783-9","volume":"19","author":"A Sharma","year":"2017","unstructured":"Sharma A, Kelly SM, Mitchell SG, Gryczynski J, O\u2019Grady KE, Schwartz RP. Update on Barriers to Pharmacotherapy for Opioid Use Disorders. Curr Psychiatry Rep. 2017;19:35.","journal-title":"Curr Psychiatry Rep"},{"key":"312_CR12","first-page":"1","volume":"0","author":"CHA Andrilla","year":"2018","unstructured":"Andrilla CHA, Moore TE, Patterson DG, Larson EH. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update. J Rural Health. 2018;0:1\u20135.","journal-title":"J Rural Health"},{"key":"312_CR13","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1016\/j.amepre.2018.01.004","volume":"54","author":"CHA Andrilla","year":"2018","unstructured":"Andrilla CHA, Patterson DG, Garberson LA, Coulthard C, Larson EH. Geographic variation in the supply of selected behavioral health providers. Am J Prev Med. 2018;54:S199\u2013207.","journal-title":"Am J Prev Med"},{"key":"312_CR14","volume-title":"Trends in the use of methadone, buprenorphine, and extended-release naltrexone at substance abuse treatment facilities: 2003-2015 (update), the CBHSQ report","author":"CE Alderks","year":"2017","unstructured":"Alderks CE. Trends in the use of methadone, buprenorphine, and extended-release naltrexone at substance abuse treatment facilities: 2003-2015 (update), the CBHSQ report; 2017."},{"key":"312_CR15","volume-title":"Drug addiction treatment act of","author":"106th U.S. Congress","year":"2000","unstructured":"106th U.S. Congress. Drug addiction treatment act of 2000. www.gpo.gov\/fdsys\/pkg\/PLAW-106publ310\/pdf\/PLAW-106publ310.pdf."},{"key":"312_CR16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1370\/afm.1735","volume":"13","author":"RA Rosenblatt","year":"2015","unstructured":"Rosenblatt RA, Andrilla CHA, Catlin M, Larson EH. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015;13:23\u20136.","journal-title":"Ann Fam Med"},{"key":"312_CR17","doi-asserted-by":"crossref","unstructured":"Goedel WC, Shapiro A, Cerd\u00e1 M, Tsai J, Hadland S, Marshall BD. Association of Racial\/Ethnic Segregation with Treatment Capacity for Opioid Use Disorder in Counties in the United States. JAMA Netw Open. 2020;3(4):e203711.","DOI":"10.1001\/jamanetworkopen.2020.3711"},{"issue":"9","key":"312_CR18","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","volume":"76","author":"PA Lagisetty","year":"2019","unstructured":"Lagisetty PA, Ross R, Bohnert ASB, Clay M, Maust DT. Buprenorphine treatment divide by race\/ethnicity and payment. JAMA Psychiatry. 2019;76(9):979\u201381.","journal-title":"JAMA Psychiatry"},{"key":"312_CR19","volume-title":"The SAMHSA Evaluation of the Impact of the DATA Waiver Program. Summary Report","author":"A Stanton","year":"2006","unstructured":"Stanton A. The SAMHSA Evaluation of the Impact of the DATA Waiver Program. Summary Report. Rockville: WESTAT; 2006."},{"key":"312_CR20","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11606-008-0881-9","volume":"24","author":"DT Barry","year":"2009","unstructured":"Barry DT, Irwin KS, Jones ES, Becker WC, Tetrault JM, Sullivan LE, et al. Integrating buprenorphine treatment into office-based practice: a qualitative study. J Gen Intern Med. 2009;24:218\u201325.","journal-title":"J Gen Intern Med"},{"key":"312_CR21","first-page":"1","volume":"15","author":"JR DeFlavio","year":"2015","unstructured":"DeFlavio JR, Rolin SA, Nordstrom BR, Kazal LA. J. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural Remote Health. 2015;15:1\u201312.","journal-title":"Rural Remote Health"},{"key":"312_CR22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1300\/J069v25n04_09","volume":"52","author":"W Kissin","year":"2006","unstructured":"Kissin W, Mcleod C, Sonnefeld J, Stanton A. Experiences of a National Sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis. 2006;52:91\u2013103.","journal-title":"J Addict Dis"},{"key":"312_CR23","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s11920-011-0222-2","volume":"13","author":"EM Oliva","year":"2011","unstructured":"Oliva EM, Maisel NC, Gordon AJ, Harris AHS. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr Psychiatr Rep. 2011;13:374\u201381.","journal-title":"Curr Psychiatr Rep"},{"key":"312_CR24","unstructured":"Madras BK, Ahmad NJ, Wen J, Sharfstein J, and the Prevention, Treatment, and Recovery Working Group of the Action Collaborative on Countering the U.S. Opioid Epidemic. NAM Perspectives. Discussion Paper, Washington, DC; 2020."},{"key":"312_CR25","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/add.14180","volume":"113","author":"BP Jarvis","year":"2018","unstructured":"Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, et al. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction. 2018;113:1188\u2013209.","journal-title":"Addiction."},{"key":"312_CR26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugpo.2017.11.021","volume":"54","author":"B Andraka-Christou","year":"2018","unstructured":"Andraka-Christou B, Capone MJ. A Qualitative Study Comparing Physician-Reported Barriers to Treating Addiction using Buprenorphine and Extended-Release Naltrexone in U.S. Office-Based Practices. Int J Drug Policy. 2018;54:9\u201317.","journal-title":"Int J Drug Policy"},{"key":"312_CR27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jsat.2015.10.003","volume":"62","author":"K Alanis-Hirsch","year":"2016","unstructured":"Alanis-Hirsch K, Croff R, Ford JH, Johnson K, Chalk M, Schmidt L, et al. Extended-release naltrexone: a qualitative analysis of barriers to routine use. J Subst Abus Treat. 2016;62:68\u201373.","journal-title":"J Subst Abus Treat"},{"key":"312_CR28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.15288\/jsad.2015.76.143","volume":"76","author":"L Aletraris","year":"2015","unstructured":"Aletraris L, Edmond MB, Roman PM. Adoption of Injectable Naltrexone in U.S. Substance Use Disorder Treatment Programs. J Studies Alcohol Drugs. 2015;76:143\u201351.","journal-title":"J Studies Alcohol Drugs"},{"key":"312_CR29","doi-asserted-by":"crossref","unstructured":"Saxon AJ, Akerman SC, Liu CC, Sullivan MA, Silverman BL, Vocci FJ. Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's cost and treatment outcomes registry. Addiction. 2018;113(8):1477\u201387.","DOI":"10.1111\/add.14199"},{"key":"312_CR30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","volume":"391","author":"JD Lee","year":"2018","unstructured":"Lee JD, Nunes EV, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391:309\u201318.","journal-title":"Lancet"},{"key":"312_CR31","doi-asserted-by":"crossref","unstructured":"Tsai AC, Kiang MV, Barnett ML, Beletsky L, Keyes KM, McGinty EE, et al. Stigma as a Fundamental Hindrance to the United States Opioid Overdose Crisis Response. PLoS Med. 2019;16(11):e1002969.","DOI":"10.1371\/journal.pmed.1002969"},{"issue":"1","key":"312_CR32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1023\/A:1014301607592","volume":"36","author":"JE Sale","year":"2002","unstructured":"Sale JE, Lohfeld LH, Brazil K. Revisiting the quantitative-qualitative debate: implications for mixed-methods research. Qual Quant. 2002;36(1):43\u201353.","journal-title":"Qual Quant"},{"issue":"1","key":"312_CR33","first-page":"95","volume":"30","author":"U Kelle","year":"2005","unstructured":"Kelle U. Sociological explanations between micro and macro and the integration of qualitative and quantitative methods. Hist Soc Res. 2005;30(1):95\u2013117.","journal-title":"Hist Soc Res"},{"key":"312_CR34","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1111\/add.14278","volume":"10","author":"KK Solli","year":"2018","unstructured":"Solli KK, ZeH L, Opheim A, Krajci P, Sharma-Haase K, Benth J\u0160, et al. Effectiveness, Safety and Feasibility of Extended-Release Naltrexone for Opioid Dependence: A Nine-Month Follow-Up to a Three-Month Randomized Trial. Addiction. 2018;10:1840\u20139.","journal-title":"Addiction"},{"key":"312_CR35","volume-title":"FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for opioid use disorder","author":"U.S. Food and Drug Administration","year":"2017","unstructured":"U.S. Food and Drug Administration. FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for opioid use disorder. 2017."},{"key":"312_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1609406917733847","volume":"16","author":"LS Nowell","year":"2017","unstructured":"Nowell LS, Norris JM, White DE, Moules NJ. Thematic analysis: striving to meet the trustworthiness criteria. Int J Qual Methods. 2017;16:1\u201313.","journal-title":"Int J Qual Methods"},{"key":"312_CR37","first-page":"347","volume":"67","author":"H Joseph","year":"2000","unstructured":"Joseph H, Stancliff S, Langrod J. Methadone Maintenance Treatment (MMT): A Review of Historical and Clinical Issues. Mount Sinai J Med. 2000;67:347\u201364.","journal-title":"Mount Sinai J Med"},{"key":"312_CR38","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3109\/00952990.2015.1059625","volume":"41","author":"AM Holbrook","year":"2015","unstructured":"Holbrook AM. Methadone versus buprenorphine for the treatment of opioid abuse in pregnancy: science and stigma. Am J Drug Alcohol Abuse. 2015;41:1097\u20139891.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"312_CR39","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s40263-013-0110-x","volume":"27","author":"YY Syed","year":"2013","unstructured":"Syed YY, Keating GM. Extended-release intramuscular naltrexone (VIVITROL\u00ae): a review of its use in the prevention of relapse to opioid dependence in detoxified patients. CNS Drugs. 2013;27:851\u201361.","journal-title":"CNS Drugs"},{"key":"312_CR40","doi-asserted-by":"crossref","unstructured":"McGovern MP, Lambert-Harris C, Gotham HJ, Claus RE, Xie H. Dual diagnosis capability in mental health and addiction treatment services: an assessment of programs across multiple state systems. Adm Policy Ment Health. 2014;41(2):205\u201314.","DOI":"10.1007\/s10488-012-0449-1"},{"key":"312_CR41","doi-asserted-by":"crossref","unstructured":"Martin CE, Longinaker N, Terplan M. Recent trends in treatment admissions for prescription opioid abuse during pregnancy. J Subst Abuse Treat. 2015;48(1):37\u201342.","DOI":"10.1016\/j.jsat.2014.07.007"},{"key":"312_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2016.10.005","volume":"74","author":"A Kermack","year":"2017","unstructured":"Kermack A, Flannery M, Tofighi B, McNeely J, Lee JD. Buprenorphine prescribing practice trends and attitudes among New York providers. J Subst Abus Treat. 2017;74:1\u20136.","journal-title":"J Subst Abus Treat"},{"key":"312_CR43","doi-asserted-by":"crossref","first-page":"544","DOI":"10.5993\/AJHB.30.5.11","volume":"30","author":"S McMurphy","year":"2006","unstructured":"McMurphy S, Shea J, Switzer J, Turner BJ. Clinic-based treatment for opioid dependence: a qualitative inquiry. Am J Health Behav. 2006;30:544\u201355.","journal-title":"Am J Health Behav"},{"key":"312_CR44","volume-title":"Substance Use Disorders and the Role of the States. The Pew Charitable Trusts & the John D. and Catherine T. MacArthur Foundaiton","author":"SK Urahn","year":"2015","unstructured":"Urahn SK, Schiff M, Bell E, Chao S, Huh K, McKillop M. Substance Use Disorders and the Role of the States. The Pew Charitable Trusts & the John D. and Catherine T. MacArthur Foundaiton; 2015."},{"key":"312_CR45","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","volume":"74","author":"L Tanum","year":"2017","unstructured":"Tanum L, Solli KK, ZeH L, Benth J\u0160, Opheim A, Sharma-Haase K, et al. The effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence. JAMA Psychiatry. 2017;74:1197\u2013205.","journal-title":"JAMA Psychiatry"},{"key":"312_CR46","doi-asserted-by":"crossref","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014(2):CD002207.","DOI":"10.1002\/14651858.CD002207.pub4"},{"key":"312_CR47","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","volume":"35","author":"C Timko","year":"2016","unstructured":"Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35:22\u201335.","journal-title":"J Addict Dis"},{"key":"312_CR48","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","volume":"109","author":"YI Hser","year":"2014","unstructured":"Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, et al. Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109:79\u201387.","journal-title":"Addiction"},{"key":"312_CR49","first-page":"112","volume-title":"Methadone, Buprenorphine and Preferences for Opioid Agonist Treatment: A Qualitative Analysis","author":"B Jo","year":"2017","unstructured":"Jo B, Yarborough H, Stumbo SP, Mccarty D, Mertens J, Weisner C, et al. Methadone, Buprenorphine and Preferences for Opioid Agonist Treatment: A Qualitative Analysis; 2017. p. 112\u20138."},{"key":"312_CR50","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jsat.2016.02.009","volume":"66","author":"LA Uebelacker","year":"2016","unstructured":"Uebelacker LA, Bailey G, Herman D, Anderson B, Stein M. Patients\u2019 beliefs about medications are associated with stated preference for methadone, buprenorphine, naltrexone, or no medication-assisted therapy following inpatient opioid detoxification. J Subst Abus Treat. 2016;66:48\u201353.","journal-title":"J Subst Abus Treat"}],"container-title":["Substance Abuse Treatment, Prevention, and Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-020-00312-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13011-020-00312-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-020-00312-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T20:04:40Z","timestamp":1631563480000},"score":1,"resource":{"primary":{"URL":"https:\/\/substanceabusepolicy.biomedcentral.com\/articles\/10.1186\/s13011-020-00312-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,14]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["312"],"URL":"https:\/\/doi.org\/10.1186\/s13011-020-00312-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-22126\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-22126\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-22126\/v3","asserted-by":"object"}]},"ISSN":["1747-597X"],"issn-type":[{"value":"1747-597X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,14]]},"assertion":[{"value":"24 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Review Board at the University of Michigan, reference number HUM00159099. All participants provided informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors have no competing interests to report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}